Mach7 Launches Flamingo Platform as Operational Reset Nears Completion
Mach7 launches Flamingo architecture as reset phase draws to a close
Mach7 Technologies (ASX: M7T) has reported its H1 FY26 results, marking a pivotal moment in the company’s operational reset. The healthcare IT firm secured its first customer for the newly launched Mach7 Flamingo Architecture in December 2025, signalling the transition from restructuring mode into what management describes as “build and deliver mode”.
Revenue for the half-year came in at A$13.7M, down 23% on the prior corresponding period, primarily due to lower capital software sales and customer churn. However, the company has strengthened its recurring revenue base, which now represents 85% of total revenue and covers 78% of operating expenses. Operating expenses were reduced by 6% to A$14.8M, reflecting disciplined cost management as the commercial and organisational reset takes effect.
The company closed the period with a cash position of A$18.5M and no debt, providing financial flexibility to execute its growth strategy. Operating cash flow turned positive in Q2 FY26, indicating improving cash generation as the business stabilises.
What is enterprise imaging architecture?
Enterprise imaging refers to the comprehensive management of all medical images across a healthcare organisation, not just those from radiology departments. A vendor neutral archive (VNA) allows hospitals to consolidate images from multiple sources, including cardiology, pathology, and ophthalmology, into a single accessible repository.
The Mach7 Flamingo Architecture Launch represents a modular, flexible platform that enables healthcare providers to consolidate all imaging data across their enterprise while leveraging existing IT infrastructure. Flamingo allows organisations to store images in native format or wrapped in DICOM, supports both on-premise and cloud deployment, and provides AI enablement within the software.
For investors, this expansion beyond traditional VNA products opens new revenue pathways. Flamingo can be sold to existing customers as an upsell or serve as a standalone entry point for new logos, diversifying revenue streams beyond archive-only sales.
When big ASX news breaks, our subscribers know first
Financials reflect disciplined cost management amid revenue reset
The 23% revenue decline to A$13.7M was driven by softer capital software sales (down 68% to A$1.1M) and professional services revenue (down 39% to A$0.9M). Recurring revenue fell 8% to A$11.6M, but its increased proportion of total revenue signals improving quality of revenue mix.
Annual Recurring Revenue (ARR) run rate remained relatively stable at A$23.0M, down just 2% on the prior corresponding period in constant currency terms. This stability demonstrates the business is holding its recurring revenue floor despite the headwinds from capital sales volatility.
| Metric | H1 FY26 | H1 FY25 | Change |
|---|---|---|---|
| Revenue | A$13.7M | A$17.7M | -23% |
| Recurring Revenue | A$11.6M | A$12.7M | -8% |
| Operating Expenses | A$14.8M | A$15.8M | -6% |
| ARR Run Rate | A$23.0M | A$23.3M | -2% |
Adjusted EBITDA came in at -A$2.3M, compared to A$0.8M in the prior corresponding period. Management attributes the decline to the absence of lumpy capital software sales, which more than offset the reduction in operating expenses. Gross margin remained high at 92%, consistent with the efficiency and scalability of the platform.
The stable ARR run rate combined with a 6% reduction in operating expenses demonstrates the company is improving unit economics while maintaining its recurring revenue base.
Balance sheet provides runway for growth investment
Mach7 closed H1 FY26 with cash of A$18.5M and no debt, down from A$23.1M at 30 June 2025. The reduction reflects operating cash outflow during the reset phase, but the company turned operating cash flow positive in Q2 FY26, indicating improving trajectory.
Cash receipts for the half were A$12.5M, with net operating cash flow of -A$3.7M. The improvement in operating cash flow through the half suggests the business is moving toward sustainable cash generation as recurring revenue stabilises and cost reductions take effect.
The balance sheet strength provides flexibility to invest in growth-critical areas, including expanded sales capacity aligned to the company’s Ideal Customer Profile (Academic Medical Centres), enhanced customer success capabilities, and ongoing product development, without near-term capital raising pressure.
Commercial engine rebuilt with new leadership and partner focus
Mach7 appointed Todd Stallard as new sales leadership in September 2025, bringing experience in driving growth across technology, commercial, government, and product development sectors. The sales organisation has been restructured with clear ownership across new customer acquisition, upsell and cross-sell activities, partner channels, and services.
The company adopted a quality-over-quantity approach at the RSNA 2025 trade show, focusing on early qualification and higher win probability leads rather than maximising booth traffic. This strategic shift reflects a more disciplined approach to pipeline development.
Sales orders for H1 FY26 totalled A$10.0M in total contract value (TCV), down from A$16.2M in the prior corresponding period. However, the composition of orders shifted significantly toward recurring revenue: ARR component of sales orders reached A$8.5M, representing 85% of total orders, compared to 62% in H1 FY25.
Todd Stallard, New Sales Leadership
Appointed in September 2025, Stallard is a seasoned sales leader with a proven track record driving growth across the technology industry in commercial, government and product development spaces. His focus is on establishing a disciplined, scalable, data-driven revenue engine across all channels.
The commercial transformation addresses a key investor concern around sales execution. With restructured ownership across customer segments and a rebuilt marketing engine, the company is positioned to convert pipeline into contracted ARR more effectively.
Flamingo pipeline building with ARR contribution expected from H2 FY26
The first Flamingo customer was signed in Q2 FY26 (October–December 2025), providing validation for the new product line. Flamingo serves dual purposes: it can be sold to existing customers as an upsell opportunity or act as a standalone entry point for new logos, reducing dependence on full VNA replacements.
Management has set realistic expectations around Flamingo’s revenue contribution, noting that meaningful ARR impact is expected in H2 FY26 and into FY27. The company is focusing on pipeline quality and execution discipline rather than rushing deployment.
Flamingo’s modular architecture supports enterprise imaging strategies by enabling AI integration, interoperability, and electronic medical record (EMR) integration. This positions Mach7 to participate in broader healthcare IT modernisation initiatives beyond traditional imaging storage.
Market tailwinds support strategic positioning
Mach7 operates in markets experiencing structural growth driven by increasing imaging volumes, AI adoption, and cloud migration trends.
- Enterprise imaging market growth: Valued at US$2.1B in 2024, the market is expected to reach US$4.1B by 2030, representing a 12% compound annual growth rate (CAGR).
- AI in medical imaging expansion: The AI in medical imaging market is projected to grow at 20-35% CAGR from US$1.3B in 2024.
- Global AI market outlook: The global AI market is projected to reach US$758B in 2025 and US$1.9T by 2030, with over 20% CAGR.
- Healthcare AI adoption trends: Approximately 90% of hospitals use AI for diagnosis and monitoring, driving efficiency and precision medicine advancements.
Mach7’s Ideal Customer Profile (ICP) focuses on Academic Medical Centres (AMCs), where the company already has over a dozen customers. AMCs typically face pain points including data fragmentation, slow image access, and vendor lock-in. Key decision makers include Chief Information Officers, Chief Medical Information Officers, and Heads of Imaging or Radiology.
These market dynamics provide a supportive backdrop for Mach7’s repositioned product suite, particularly as Flamingo enables healthcare organisations to consolidate imaging data and integrate AI capabilities.
The next major ASX story will hit our subscribers first
Outlook priorities for H2 FY26
Management has articulated clear priorities for the second half of FY26:
- Sign new customer contracts
- Increase visibility of expansion opportunities within the install base
- Invest in additional resources to support Asia sales opportunities
- Ensure Flight Crew customer engagement pods are fully operational
- Enhance accountability via structured “week plans”
- Hire a Chief Technology Officer and embed them in the business
- Expand sales capacity aligned to ICP, partners, and regions
- Relocate headquarters to reduce costs and optimise staff engagement
- Invest in growth-critical capabilities that meet return on investment hurdles
The company continues to pursue Medical Device Regulation (MDR) compliance and CE Mark certification, supporting regulatory pathways for European and Middle East expansion.
Mach7 remains focused on disciplined cost management while selectively investing in growth-supporting capabilities across sales execution, product development, and platform scalability. The balance sheet provides capacity to execute this strategy without near-term funding pressure.
For investors, the H1 FY26 result provides evidence that the operational reset is largely complete. With Flamingo now in market, a rebuilt commercial organisation, and stable recurring revenue covering the majority of operating expenses, execution risk is reducing while growth optionality increases through the expanded product suite.
Want the Next Healthcare IT Breakout in Your Inbox?
Join 20,000+ investors receiving FREE real-time ASX alerts with expert analysis, delivered within minutes of announcement. Big News Blast covers healthcare tech, finance, consumer, and manufacturing—everything non-resource. Click the “Free Alerts” button to get breaking market-moving news before the crowd reacts.